Stifel lowered the firm's price target on Nurix Therapeutics to $34 from $35 and keeps a Buy rating on the shares after the company reported a GAAP net loss that was wider than the firm's and consensus estimates, primarily driven by the recognition of lower-than-expected collaborative revenue. Registrational bexobrutideg development plans in CLL continue to progress, with patient enrollment into the Phase 2 DAYBreak CLL-201 trial ongoing and initiation of the confirmatory Phase 3 DAYBreak CLL-306 now anticipated to begin enrolling patients in mid-2026, the analyst noted.
